<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194843</url>
  </required_header>
  <id_info>
    <org_study_id>DPO-Hepatectomy</org_study_id>
    <secondary_id>ET2007-073</secondary_id>
    <secondary_id>2007-007968-19</secondary_id>
    <nct_id>NCT01194843</nct_id>
  </id_info>
  <brief_title>Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations</brief_title>
  <acronym>DPO</acronym>
  <official_title>A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Apicil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and impact on morphine consumption of
      ropivacaine administered by local per and post hepatic surgery infiltration.

      Patients will be randomized to either ropivacaine or physiological serum, with equivalent
      administration modalities in both arms.

      Patients will be followed during 4 days after the surgery. They will also come back for a
      follow-up visit one month later.

      It is necessary to enrol 100 patients. The estimated period of inclusion is 24 months.

      This is a prospective, comparative, monocentric, double-blind randomized study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of ropivacaine versus physiological serum administered by local infiltration and impact on morphine consumption</measure>
    <time_frame>In the 4 days following the hepatectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ropivacaine versus physiological serum administered by local infiltration and impact on daily morphine consumption</measure>
    <time_frame>In the 4 days following the hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patients' perception of post-surgery pain</measure>
    <time_frame>In the 4 days following the hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate and late complications related to the perfusion, the medical device and other predictable side effects</measure>
    <time_frame>In the 4 days following the hepatectomy and one month later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' post-surgery rehabilitation</measure>
    <time_frame>Between surgery and follow-up visit, one month later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with the pain care</measure>
    <time_frame>Four days after the hepatectomy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Hepatectomy</condition>
  <condition>Pain</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine administration by local per and post surgery infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological serum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of physiological serum by local per and post surgery infiltration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological serum</intervention_name>
    <description>40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy</description>
    <arm_group_label>Physiological serum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥ 18 years

          -  Patients with histologically confirmed cancer

          -  Patients treated at the Centre Léon Bérard

          -  Patients requiring a surgery for hepatic metastases

          -  ASA &lt;= 3

          -  At least 3 weeks between surgery and chemotherapy

          -  Total bilirubin &lt; 1.5 x upper limit of normal range

          -  ASAT and ALAT &lt; 5 times x upper limit of normal range

          -  Creatinine clearance &gt; 60 ml per hour

          -  Serum creatinine &lt; 115 µmol/l

          -  Mandatory affiliation with a health insurance system

          -  Patients able to understand French

          -  Signed, written informed consent

        Exclusion Criteria:

          -  Patients with a hepatocellular carcinoma or an initial liver cancer

          -  Patients treated chronically by morphine

          -  Patients that already have abdominal pain

          -  Patients who are allergic either to morphinics, local anesthesics, paracetamol, NSAID
             or cortisone

          -  Patients suffering from heart, kidney or liver insufficiency

          -  Documented history of cognitive or psychiatric disorders

          -  Pregnant or lactating women

          -  Difficult follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique Peres-Bachelot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>LYON Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Beaussier M, El'Ayoubi H, Schiffer E, Rollin M, Parc Y, Mazoit JX, Azizi L, Gervaz P, Rohr S, Biermann C, Lienhart A, Eledjam JJ. Continuous preperitoneal infusion of ropivacaine provides effective analgesia and accelerates recovery after colorectal surgery: a randomized, double-blind, placebo-controlled study. Anesthesiology. 2007 Sep;107(3):461-8.</citation>
    <PMID>17721249</PMID>
  </reference>
  <reference>
    <citation>Bianconi M, Ferraro L, Ricci R, Zanoli G, Antonelli T, Giulia B, Guberti A, Massari L. The pharmacokinetics and efficacy of ropivacaine continuous wound instillation after spine fusion surgery. Anesth Analg. 2004 Jan;98(1):166-72, table of contents.</citation>
    <PMID>14693613</PMID>
  </reference>
  <reference>
    <citation>Borromeo CJ, Stix MS, Lally A, Pomfret EA. Epidural catheter and increased prothrombin time after right lobe hepatectomy for living donor transplantation. Anesth Analg. 2000 Nov;91(5):1139-41.</citation>
    <PMID>11049898</PMID>
  </reference>
  <reference>
    <citation>Godier A, Babinet A, el Metaoua S, Fulgencio JP, Bonnet F. [A new cause of postoperative confusion syndrome: nefopam]. Ann Fr Anesth Reanim. 2002 Jun;21(6):538-9. French.</citation>
    <PMID>12134601</PMID>
  </reference>
  <reference>
    <citation>Ho AM, Lee A, Karmakar MK, Samy W, Lai PB, Ho OA, Cho A. Hemostatic parameters after hepatectomy for cancer. Hepatogastroenterology. 2007 Jul-Aug;54(77):1494-8.</citation>
    <PMID>17708283</PMID>
  </reference>
  <reference>
    <citation>Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe? Lancet. 2006 Dec 23;368(9554):2195-6.</citation>
    <PMID>17189017</PMID>
  </reference>
  <reference>
    <citation>Kwan AL. Epidural analgesia for patient undergoing hepatectomy. Anaesth Intensive Care. 2003 Apr;31(2):236-7.</citation>
    <PMID>12712800</PMID>
  </reference>
  <reference>
    <citation>Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007 Aug;11(3):525-48, vi. Review.</citation>
    <PMID>17723918</PMID>
  </reference>
  <reference>
    <citation>Liu SS, Richman JM, Thirlby RC, Wu CL. Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. J Am Coll Surg. 2006 Dec;203(6):914-32. Epub 2006 Oct 25. Review.</citation>
    <PMID>17116561</PMID>
  </reference>
  <reference>
    <citation>Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007 Jul;105(1):70-8.</citation>
    <PMID>17578959</PMID>
  </reference>
  <reference>
    <citation>Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005 Jun;33(3):311-22. Review.</citation>
    <PMID>15973913</PMID>
  </reference>
  <reference>
    <citation>Schumann R, Zabala L, Angelis M, Bonney I, Tighiouart H, Carr DB. Altered hematologic profiles following donor right hepatectomy and implications for perioperative analgesic management. Liver Transpl. 2004 Mar;10(3):363-8.</citation>
    <PMID>15004762</PMID>
  </reference>
  <reference>
    <citation>Tsui SL, Yong BH, Ng KF, Yuen TS, Li CC, Chui KY. Delayed epidural catheter removal: the impact of postoperative coagulopathy. Anaesth Intensive Care. 2004 Oct;32(5):630-6.</citation>
    <PMID>15535484</PMID>
  </reference>
  <reference>
    <citation>Urwin SC, Smith HS. Fatal nefopam overdose. Br J Anaesth. 1999 Sep;83(3):501-2.</citation>
    <PMID>10655934</PMID>
  </reference>
  <reference>
    <citation>Villier C, Mallaret MP. Nefopam abuse. Ann Pharmacother. 2002 Oct;36(10):1564-6.</citation>
    <PMID>12243607</PMID>
  </reference>
  <reference>
    <citation>Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G, Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008 Jul;62(2):195-201. Epub 2007 Sep 28.</citation>
    <PMID>17901955</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

